Working… Menu

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy (CBD1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02815540
Recruitment Status : Terminated (Investigator on medical leave, and difficult recruitment)
First Posted : June 28, 2016
Last Update Posted : February 12, 2021
Information provided by (Responsible Party):
Gillette Children's Specialty Healthcare

Brief Summary:
The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), when the CBD is administered as an artisanal oil obtained through state dispensaries or other sources. The intent is to begin to assess potential risks and benefits of this therapy in a vulnerable patient population by characterizing the effects of CBD on EKG findings, heart rate variability and the occurrence of seizures.

Condition or disease Intervention/treatment Phase
Lennox-Gastaut Syndrome Dravet Syndrome Procedure: 12-Lead ECG Drug: Cannabidiol Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children
Actual Study Start Date : February 16, 2017
Actual Primary Completion Date : December 1, 2018
Actual Study Completion Date : December 1, 2018

Arm Intervention/treatment
This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
Procedure: 12-Lead ECG
Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
Other Name: Holter Monitor

Drug: Cannabidiol
Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.

Primary Outcome Measures :
  1. Holter SDNN parameter change [ Time Frame: Baseline to 4 to 8 week follow up visit ]
    Change from baseline Holter SDNN parameter to follow up visit Holter SDNN parameter.

Secondary Outcome Measures :
  1. Seizure frequency [ Time Frame: Baseline and 4 to 8 week follow up visit ]
    Change from baseline seizure frequency to follow up visit seizure frequency.

  2. Dysautonomia signs and symptoms [ Time Frame: Baseline and 4 to 8 week follow up visit ]
    signs and symptoms assessed by questionnaire developed for this study that documents observable signs and symptoms of dysautonomia

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with Dravet syndrome or Lennox-Gastaut syndrome
  • Patients who are planning to obtain medical cannabidiol
  • Patients who are already taking medical cannabidiol and are planning to stop taking it

Exclusion Criteria:

  • Patients without a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02815540

Layout table for location information
United States, Minnesota
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, United States, 55101
Sponsors and Collaborators
Gillette Children's Specialty Healthcare
Layout table for investigator information
Principal Investigator: Beverly S Wical, MD Gillette Children's Specialty Healthcare
1. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (eds) Epileptic syndromes in infancy, childhood and adolescence, 4th ed. John Libbey, London, 2005, pp 89 - 109.
2., Retrieved 6.10.2015
7. Wical, B, Wendorf H, Leighty D, Tervo M, Tervo R. Signs of Dysautonomia in Children with Dravet Syndrome. Presented at the Annual Meeting of the American Epilepsy Society, Boston, MA, Dec 2009.
15. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister L. (1984). Single dose kinetics of cannabidiol in man. Cannabinoids: chemical, pharmacologic, and therapeutic aspects. S. Agurell, W. L. Dewey and R. Willette. Orlando, FL, Academic Press Inc.: 219-225. doi: 10.1016/B978-0-12-044620-9.50003-8

Layout table for additonal information
Responsible Party: Gillette Children's Specialty Healthcare Identifier: NCT02815540    
Other Study ID Numbers: CBD-001
First Posted: June 28, 2016    Key Record Dates
Last Update Posted: February 12, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Myoclonic
Lennox Gastaut Syndrome
Pathologic Processes
Epilepsy, Generalized
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes
Genetic Diseases, Inborn